Dania Alhyari | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assist. Prof. Dr. Dania Alhyari | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Assistant Professor at Petra University, Jordan

Dr. Dania Alhyari is an accomplished pharmaceutical sciences researcher and assistant professor with over a decade of experience in academia, research, and mentorship. Her expertise lies in drug formulation, permeability, solubility, and phytochemistry, with a strong focus on enhancing drug bioavailability and therapeutic efficacy. She earned her Ph.D. in Pharmaceutical Sciences from the University of Bradford, UK, and a Master’s in Molecular Biology from the University of Ottawa, Canada. Throughout her career, she has been actively involved in teaching and research, currently serving as an Assistant Professor at Petra University, Jordan, where she mentors graduate students and leads research projects on novel drug delivery systems. Previously, she was a Postdoctoral Fellow at the University of Bradford, where she collaborated on interdisciplinary research and presented findings at international conferences. Dr. Alhyari has published extensively in reputed journals, contributing to advancements in pharmaceutical sciences. Her work emphasizes the integration of molecular biology with drug formulation to optimize therapeutic outcomes. She has also received recognition for her academic contributions, including invitations to speak at conferences and research grants for her studies. With a strong background in teaching, research, and international collaboration, Dr. Alhyari continues to make significant contributions to pharmaceutical innovation.

Professional Profile

Education

Dr. Dania Alhyari holds a strong academic background in pharmaceutical sciences and molecular biology, which has shaped her expertise in drug formulation and biopharmaceutical research. She earned her Ph.D. in Pharmaceutical Sciences from the University of Bradford, UK, where she focused on drug permeability and solubility studies, developing innovative methodologies to enhance drug bioavailability. Her doctoral research involved interdisciplinary collaborations and was presented at several international conferences. Prior to her Ph.D., she completed a Master’s degree in Molecular Biology at the University of Ottawa, Canada, where she gained in-depth knowledge of biochemical and genetic interactions related to pharmaceutical applications. During her master’s studies, she engaged in extensive laboratory work, investigating drug interactions at the molecular level. Her academic journey began with a Bachelor’s degree in Pharmacy, where she developed a solid foundation in drug formulation, pharmacokinetics, and analytical techniques. Throughout her education, Dr. Alhyari actively participated in research projects, contributing to publications and advancing pharmaceutical knowledge. Her diverse educational background, spanning pharmacy, molecular biology, and pharmaceutical sciences, has provided her with a multidisciplinary perspective that enhances her research capabilities. With a commitment to scientific discovery, her education has been instrumental in shaping her career in academia and pharmaceutical research.

Professional Experience

Dr. Dania Alhyari has amassed extensive professional experience in pharmaceutical research and academia, contributing significantly to drug formulation, solubility, and permeability studies. She currently serves as an Assistant Professor at Petra University, Jordan, where she teaches advanced courses in pharmaceutics and pharmaceutical technology while mentoring graduate students in innovative drug delivery research. In this role, she leads research projects exploring novel drug formulations and collaborates with international experts to enhance pharmaceutical applications. Prior to this, she worked as a Postdoctoral Fellow at the University of Bradford, UK, where she developed cutting-edge methodologies for drug permeability and solubility studies. During her postdoctoral tenure, she mentored students, presented her findings at international conferences, and worked closely with interdisciplinary teams to advance pharmaceutical research. Earlier in her career, Dr. Alhyari served as a Research and Teaching Assistant at Petra University, where she played a key role in curriculum development, laboratory research, and student mentorship. She co-authored multiple research papers and contributed to the design of laboratory experiments that enhanced the university’s pharmaceutical research capabilities. Her professional journey reflects a strong balance between research, teaching, and leadership, positioning her as a key contributor to the advancement of pharmaceutical sciences and education.

Research interest

Dr. Dania Alhyari’s research interests lie at the intersection of drug formulation, permeability, solubility, and phytochemistry, with a focus on optimizing drug delivery systems for improved therapeutic outcomes. She is particularly interested in enhancing the bioavailability of pharmaceutical compounds by studying their physicochemical and biopharmaceutical properties. Her work explores innovative drug delivery mechanisms, including novel excipients, nanoformulations, and targeted drug transport to improve drug absorption and efficacy. Additionally, she investigates the role of natural compounds in pharmaceutical sciences, studying their antioxidant, anti-inflammatory, and bioavailability-enhancing properties. Through interdisciplinary collaborations, she integrates molecular biology techniques with pharmaceutical sciences to better understand drug interactions at the cellular and molecular levels. Dr. Alhyari is also passionate about the development of more efficient and patient-friendly pharmaceutical formulations, ensuring safer and more effective therapeutic interventions. Her research extends to the evaluation of drug-excipient interactions, solubility enhancement strategies, and the design of pharmaceutical formulations that cater to specific medical needs. By combining experimental research with advanced analytical techniques, she aims to contribute to the evolution of drug development and pharmaceutical innovation. Her research efforts have been recognized through publications in high-impact journals and presentations at international conferences.

Award & Honor

Dr. Dania Alhyari has received several awards and honors in recognition of her outstanding contributions to pharmaceutical sciences, research, and education. Her dedication to advancing drug formulation and delivery systems has earned her invitations to present her findings at prestigious international conferences, where she has been acknowledged for her innovative research. She has also secured research grants that have supported her studies in drug permeability, solubility enhancement, and pharmaceutical applications, further demonstrating the significance of her work. Throughout her academic career, she has been recognized for excellence in teaching and mentorship, guiding both undergraduate and graduate students in pharmaceutical research. Her contributions to scientific literature, including publications in high-impact journals, have been widely cited, highlighting the relevance of her research in the global pharmaceutical community. Additionally, she has collaborated with leading researchers from renowned institutions in the UK and Canada, receiving commendations for her interdisciplinary work in pharmaceutical sciences and molecular biology. Dr. Alhyari’s commitment to research excellence, innovation, and education continues to be acknowledged through various accolades, reinforcing her position as a leading researcher in her field. Her achievements reflect her dedication to pushing the boundaries of pharmaceutical research and inspiring future scientists.

Conclusion

Dania Alhyari is a strong candidate for the Best Researcher Award due to her research output, international collaborations, and academic contributions. However, strengthening aspects like grant funding, patents, and research impact metrics would further solidify her case.

Publications Top Notes

  • Physicochemical and biopharmaceutical characterization of new sulfonamide derivatives of gallic acid

    • Author(s): D. Alhyari, H. Sheldrake, S. Kantamneni, M. Isreb, S.J. Soumehsaraei, et al.

    • Year: 2022

    • Citations: 4

  • Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic Acid

    • Author(s): D. Alhyari, N.A. Qinna, H.M. Sheldrake, S. Kantamneni, B.Y. Ghanem, et al.

    • Year: 2025

    • Citations: Not available yet (recent publication)

  • Physicochemical and biopharmaceutical characterization of novel derivatives of gallic acid

    • Author(s): D.H. Alhyari

    • Year: 2022

    • Citations: Not available (Thesis/Dissertation)

 

Anthony Mullin | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Mr. Anthony Mullin | Pharmaceutical Science | Best Researcher Award

PhD Research Molecular Biology, University of Hertfordshire, United Kingdom

Anthony James Mullin is a dedicated researcher with a profound passion for advancing knowledge in tissue culture management and forensic analytical chemistry. His strong academic background and extensive experience in both research and commercial settings make him a vital contributor to the fields of cancer research and psychoactive substance analysis.

Profile

Orcid

Strengths for the Award

Anthony Mullin demonstrates a solid foundation of research expertise, particularly in areas such as psychopharmacology, drug misuse, and analytical chemistry. His work, especially in forensic analysis and the study of New Psychoactive Substances (NPS), reflects innovative approaches, such as applying AI for historical drug misuse trend analysis. His collaboration with renowned researchers like Professor Schifano and Dr. Guirguis further highlights his contributions. Mullin’s research has been recognized at international conferences, underscoring its impact and relevance. His Oxford Press Award for Outstanding Achievements in Bioscience adds to his credibility. Mullin’s well-rounded skill set, including tissue culture management and advanced drug stability analysis, combined with his technical proficiency (e.g., UHPLC, GCMS) and multidisciplinary publications, strengthens his candidacy for the award.

Areas for Improvement

While Mullin’s research portfolio is impressive, his Research Influence (RI) score of 7.0 could benefit from more citations to increase visibility and impact within the academic community. His work, although influential in niche areas, might gain broader recognition by focusing on publishing in higher-impact journals and increasing collaboration beyond his current research groups. Additionally, more outreach and involvement in global networks could amplify his contributions. Although he has presented at international conferences, consistent engagement with the wider research community through more frequent publications and presentations could enhance his profile.

Education 🎓

Anthony graduated with a 1st Class BSc (Hons) in Chemical Biology from the University of Hertfordshire in 2012. His remarkable academic performance earned him the prestigious Oxford Press Award for Outstanding Achievements in Bioscience, underscoring his commitment to excellence in the field of biosciences.

Experience 💼

Anthony has served as a Freelance Research Assistant and Author at the University of Hertfordshire and Swansea University, where he worked within the Psychopharmacology, Drug Misuse, and NPS research group. His previous roles include Research Assistant and Laboratory Technician at the University of Hertfordshire, as well as positions in scientific recruitment and quality control analysis. His diverse experience has equipped him with a unique skill set that bridges the gap between scientific research and practical application.

Research Interests 🔬

Anthony’s research interests are centered around tissue culture management, bio-assay development, and the forensic analysis of new psychoactive substances (NPS). He is particularly interested in utilizing artificial intelligence to enhance analytical methodologies and improve drug stability testing processes.

Awards 🏆

Anthony has received several accolades, including the Oxford Press Award for Outstanding Achievements in Bioscience for his exceptional academic performance. His contributions to research have also led to presentations at prestigious conferences, further establishing him as a respected figure in his field.

Publications Top Notes 📝

  1. Mullin, A., Scott, M., Vaccaro, G., Floresta, G., Arillotta, D., Catalani, V., Corkery, J.M., Stair, J.L., Schifano, F., Guirguis, A. (2024). Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. Pharmacy 12, 13.
    • Citations: 0
  2. Mullin, A., Scott, M., Vaccaro, G., Gittins, R., Ferla, S., Schifano, F., Guirguis, A. (2023). Handheld Raman Spectroscopy in the First UK Home Office Licensed Pharmacist-Led Community Drug Checking Service. Int. J. Environ. Res. Public Health 20, 4793.
    • Citations: 3
  3. Williams D T, Straw N, Townsend M, Wilkinson A S, and Mullin, A. (2013). Monitoring oak processionary moth Thaumetopoea processionea L. using pheromone traps: the influence of pheromone lure source, trap design and height above the ground on capture rates. Agricultural and Forest Entomology 15, pp.126–134.
    • Citations: 20

Conclusion

Anthony Mullin is a promising researcher with significant achievements in psychopharmacology, drug misuse, and analytical chemistry. His technical skills, innovative approaches, and notable academic accomplishments make him a strong candidate for the “Best Researcher Award.” With targeted efforts to increase the visibility and impact of his work, particularly through citations and global collaboration, Mullin could further solidify his standing in the research community

Yan Ni | Pharmaceutical Research | Best Researcher Award

Posted on by ScienceFather

Dr. Yan Ni | Pharmaceutical Research | Best Researcher Award

Executive Director, Passage bio, United States

Profile

Google Scholar

Researcher Evaluation for “Best Researcher Award”

Strengths for the Award:

Extensive Expertise in Drug Development: Yan G. Ni, PhD, has over 15 years of experience in drug development, particularly in small molecules, biologics, and gene therapies. His work spans several critical therapeutic areas, including neurological and cardiovascular diseases, immune-oncology, hematology, and rare diseases. His contributions to IND/CTA submissions and regulatory interactions further highlight his deep involvement in the field.

Leadership in Translational Biomarker and Precision Medicine: Dr. Ni has demonstrated significant expertise in integrating preclinical and clinical biomarker strategies, contributing to the successful design and execution of biomarker-based clinical endpoints. His role in implementing PK and immunogenicity strategies across different phases of studies showcases his ability to bridge the gap between research and clinical application, a crucial factor in modern drug development.

Proven Management Skills: Dr. Ni’s management experience is evident in his ability to build and lead high-performing cross-functional teams. His leadership roles in international professional organizations like the AAPS and SAPA, as well as his track record of mentoring and inspiring others, underline his effectiveness as a leader in both scientific and organizational contexts.

High Scientific Productivity: With over 35 peer-reviewed publications, several book chapters, and six U.S. patents, Dr. Ni’s scientific output is substantial. His contributions to industry white papers and his role as an organizer and invited speaker at national and international conferences further affirm his thought leadership in the field.

Recognition and Awards: Dr. Ni has received numerous prestigious awards, such as the Passage Bio High Impact Award, Regeneron High Impact Award, AAPS Excellence in Ligand Binding Assays Award, and Merck Award of Excellence. These accolades reflect his high-impact contributions to the field and recognition by peers and industry leaders.

Areas for Improvement:

Broader Impact Beyond Specialized Fields: While Dr. Ni’s expertise is well-recognized within specialized areas such as biomarkers, precision medicine, and drug development, expanding his influence into broader, interdisciplinary research domains could enhance his candidacy for a “Best Researcher Award.” For example, engaging in research that impacts public health or other critical global issues might increase his visibility and impact.

Further Innovation in Emerging Therapeutic Areas: While Dr. Ni has made significant contributions to established therapeutic areas, greater involvement in cutting-edge fields such as artificial intelligence in drug discovery or personalized medicine could position him as a pioneer in these rapidly evolving areas.

Enhanced Collaboration with Global Initiatives: Although Dr. Ni has demonstrated leadership in professional organizations and consortia, expanding his collaborative efforts to include global health initiatives or large-scale, multi-national research projects could further amplify his contributions and align with broader global research priorities.

Professional Experience

Passage Bio, Philadelphia, PA
Executive Director, Biomarkers and Precision Medicine
2021-Present
Senior Director, Head of Biomarkers and Precision Medicine
2020-2021

Built and led a high-performing team responsible for driving clinical biomarker, PK/biodistribution, immunogenicity studies, and supporting clinical operations.

Developed and implemented biomarker, PK, and immunogenicity strategies to inform decision-making for neurodegenerative disease portfolios.

Led biomarker and precision medicine support for IND/CTA submissions and global regulatory interactions.

Oversaw partnerships with external CROs and laboratories, and collaborated with Clinical Study Teams on biomarker inclusion in clinical portfolios.

Regeneron, Tarrytown, NY
Associate Director, Precision Medicine, Early Clinical Development & Experimental Sciences
2016-2020

Designed and implemented biomarker strategies to support dose selection and efficacy readings for complement-mediated rare diseases.

Provided strategic leadership for discovery and early cardiovascular programs, influencing biomarker-driven decisions on target validation, disease indication selection, and patient stratification.

Led multiple biomarker-focused natural history studies with academic and clinical centers.

Bristol Myers Squibb, Princeton, NJ
Senior Research Investigator II, R&D/PD/ABD/BAS-Biologics
2012-2016

Supported biomarker bioanalytical strategy implementation for immuno-oncology, immunology, and cardiovascular diseases.

Supervised biomarker method development and validation by internal staff and CROs.

Provided strategic and technical input on biomarker bioanalytical plans, resources, and timelines for FIH and PoC studies.

Merck & Co., Inc., Rahway, NJ
Senior Research Scientist, Cardiovascular Franchise Atherosclerosis Group
2007-2011

Led the development of a 2nd generation fully human monoclonal antibody for PCSK9.

Established ELISA-based pharmacodynamics and target engagement biomarker assays.

University of Texas Southwestern Medical Center, Dallas, TX
Research Assistant Professor, Internal Medicine Department, Cardiology
2001-2007
Research Scientist, Department of Pharmacology & Alliance for Cellular Signaling
2001-2007

Conducted research on cardiac hypertrophy, heart failure, and aging, focusing on Akt and FOXO transcriptional factors.

Education and Training

Persuasive Leadership Development: Wharton Business School, University of Pennsylvania

Postdoctoral Training: Yale University, under Professors Gary Rudnick and Eric Nestler

Ph.D. in Neuroscience: University of California, Irvine, under Professor Ricardo Miledi

M.S. in Pharmacology: Institute of Basic Medical Sciences, Beijing, China

B.S. in Biochemistry: Anhui University, Hefei, China

Professional Honors

Passage Bio High Impact Award (2021)

Regeneron High Impact Award and Multiple STAR Awards (2016-2020)

AAPS Excellence in Ligand Binding Assays Award (2015)

BMS R&D ROC Award and Multiple STAR Awards (2014)

Merck Award of Excellence (2007, 2008, 2009)

Professional Affiliations

American Association of Pharmaceutical Scientists (AAPS):

Founding Member and Chair of the Biomarkers and Translational Medicine Community

Founding Member and Chair of the Gene and Cell Therapeutic Products Community

Sino-American Pharmaceutical Professionals Association (SAPA):

Director for Public Outreach and Executive Committee Member

Publications

Yang, J., Mapelli, C., Wang, Z., et al. (2022). An Optimized Agonist Peptide of Protease-activated Receptor 4 and its Use in a Platelet Aggregation Assay to Monitor the Pharmacodynamic Effects of PAR4 Antagonists. Platelets. DOI: 10.1080/09537104.2022.2053091

Hays, A., Amaravadi, L., Fernandez-Metzler, C., et al. (2022). Is Incurred Sample Reanalysis (ISR) applicable in Biomarker Assays? AAPS J, 24:65. DOI: 10.1208/s12248-022-00708-y

Ni, Y.G., King, L., Fernández-Metzler, C. (2022). Recent Progress in Biomarker Bioanalysis and Target Engagement in Bioanalytical Aspects in Biological Therapeutics. ISBN: 9781119523215. Edited by Xu, X. & Xu, W.

Conclusion:

Dr. Yan G. Ni, PhD, is an outstanding candidate for the “Best Researcher Award” based on his extensive contributions to drug development, biomarker research, and precision medicine. His leadership, scientific productivity, and recognition by peers make him a strong contender for the award. However, expanding his research impact into broader and more emerging fields could further strengthen his profile for this prestigious recognition.